CD8A and neoplasm: It was shown that a single low-dose vaccination with any of the three gDE7 mRNA vaccines activated CD8 + T cells specific to E7, produced memory T cell responses that could stop tumor relapses, and eliminated subcutaneous tumors at various stages of development.